SCHEMBL3465335

SCHEMBL3465335

CC(C)(N)c1ccnc(S(C)(=O)=O)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 1/20 0.36
▸ NOS3 P29474 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ SCN10A Q9Y5Y9 4/20 0.35
▸ SYK P43405 1/20 0.33
▸ AAK1 Q2M2I8 2/20 0.33
▸ PIK3C3 Q8NEB9 1/20 0.33
▸ ROCK1 Q13464 1/20 0.33
▸ PIK3CD O00329 1/20 0.32
▸ PIP5K1C O60331 1/20 0.32
▸ PIK3CB P42338 1/20 0.32
▸ PI4KA P42356 1/20 0.32
▸ PIK3CG P48736 1/20 0.32
▸ PI4KB Q9UBF8 1/20 0.32
▸ ALOX5AP P20292 1/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ LMNA P02545 2/20 0.31
▸ POLB P06746 1/20 0.31
▸ ADRB2 P07550 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2616432 0.85 CA1 (0.40) CCR1SCN10ASYKLMNAPOLB
SCHEMBL3465270 0.83 MASTL (0.36) CCR1SCN10ASYKAAK1PIK3C3
SCHEMBL22020323 0.82 CCR1 (0.39) CCR1SCN10ASYKPIK3C3LMNA
SCHEMBL3464628 0.81 CCR1 (0.33) CCR1SCN10AAAK1PIK3CDPIP5K1C
SCHEMBL14376068 0.76 CYP2C9 (0.34) NOS3NOS2ROCK1LMNAKDM4E
SCHEMBL2643084 0.73 L3MBTL1 (0.42) NOS3NOS2PIK3C3ROCK1PIK3CD
Hydrochloric Acid SCHEMBL18228284 0.72 L3MBTL1 (0.41) NOS3NOS2PIK3C3ROCK1PIK3CD
SCHEMBL24499831 0.71 CA1 (0.38) LMNAPOLBKDM4EALDH1A1CA1
SCHEMBL2643186 0.71 UHRF1 (0.48) CCR1NOS3NOS2LMNAPOLB
SCHEMBL10920036 0.71 ROCK1 (0.40) ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2346868-B1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2016-01-27 — — EP disclosed
US-8338610-B2 Pyridinyl compounds useful as intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-25 — — US disclosed
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-31 — — US disclosed
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093724-A1 Azaindazole Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCR4 CCR1 1/4885NOS3 1730/4885NOS2 2353/4885
US-20120136158-A1 Pyridinyl Compounds Useful As Intermediates CCR1, CCRL2, CCR4 CCR1 1/4885NOS3 1474/4885NOS2 1628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback